基于心电图的风险因素对COPD不良心肺事件及治疗结局的预测价值
该研究为IMPACT试验的事后分析,纳入9448例COPD患者,评估心电图标记物CIIS和P pulmonale对不良心肺事件的预测价值。结果显示CIIS≥20和P pulmonale均与全因死亡、住院或死亡、严重COPD急性加重等风险增加相关,联合模型风险更高;在CIIS≥20患者中,FF/UMEC/VI相比UMEC/VI可降低全因死亡和心血管不良事件风险。
要点
- CIIS≥20与全因死亡、住院或死亡、心血管不良事件及COPD急性加重风险增加相关。
- P pulmonale与全因死亡、住院或死亡及严重COPD急性加重风险增加相关。
- CIIS≥20且P pulmonale患者全因死亡风险OR为3.38,联合模型提示风险更高。
核心结论
- CIIS和P pulmonale可能作为COPD患者不良心肺事件的临床相关风险指标。
研究设计与样本
- IMPACT试验的事后分析,纳入9448例患者,按CIIS阈值(<20 vs ≥20)和基线P pulmonale分层分析。
主要发现
- CIIS≥20患者全因死亡OR 1.73(95%CI 1.27-2.37,p<0.001),住院或死亡OR 1.33(95%CI 1.17-1.50,p<0.001)。
- CIIS≥20患者心血管不良事件OR 1.27(95%CI 1.08-1.48,p<0.005),严重COPD急性加重OR 1.41(95%CI 1.21-1.64,p<0.001)。
- P pulmonale患者全因死亡OR 2.25(95%CI 1.54-3.29,p<0.001),住院或死亡OR 1.51(95%CI 1.28-1.79,p<0.001)。
- P pulmonale患者严重COPD急性加重OR 2.00(95%CI 1.65-2.41,p<0.001),中/重度急性加重OR 1.25(95%CI 1.08-1.46,p<0.001)。
- CIIS≥20且P pulmonale患者全因死亡OR 3.38(95%CI 1.23-9.30,p=0.019),住院或死亡OR 1.61(95%CI 1.14-2.22,p=0.004)。
关键数值与推荐
- CIIS≥20且P pulmonale患者严重COPD急性加重OR 1.89(95%CI 1.22-2.91,p=0.004),中/重度急性加重OR 1.25(95%CI 1.00-1.56,p=0.046)。
- 在CIIS≥20患者中,FF/UMEC/VI相比UMEC/VI降低全因死亡和心血管不良事件风险,CIIS<20患者中未观察到该效应。
临床怎么用
- 对COPD患者可考虑使用心电图标记物CIIS和P pulmonale进行风险分层,识别不良心肺事件高风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD has high mortality, compounded by comorbid cardiovascular disease. We investigated two ECG markers, Cardiac Infarction Injury Score (CIIS) and P pulmonale, as prognostic tools for adverse cardiopulmonary events in COPD. METHODS: This was a p ost hoc analysis of the IMPACT trial. Outcomes included odds (odds ratio, 95% confidence intervals) of adverse cardiopulmonary events stratified by CIIS threshold (<20 versus ≥20) and P pulmonale (baseline). Events included all-cause death, hospitalisation or death, cardiovascular adverse event of special interest, severe COPD exacerbations, and moderate/severe COPD exacerbations. We also assessed the effects of fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol or umeclidinium/vilanterol based on CIIS and P pulmonale. RESULTS: We included 9448 patients. Patients with CIIS ≥20 (versus CIIS <20) had greater odds of all-cause death (OR 1.73, 95% CI 1.27-2.37, p<0.001), hospitalisation or death (OR 1.33, 95% CI 1.17-1.50, p<0.001), cardiovascular adverse event of special interest (OR 1.27, 95% CI 1.08-1.48, p<0.005), severe COPD exacerbations (OR 1.41, 95% CI 1.21-1.64, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.13-1.40, p<0.001). Patients with P pulmonale (versus without) had greater odds of all-cause death (OR 2.25, 95% CI 1.54-3.29, p<0.001), hospitalisation or death (OR 1.51, 95% CI 1.28-1.79, p<0.001), severe COPD exacerbations (OR 2.00, 95% CI 1.65-2.41, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.08-1.46, p<0.001). A combined model demonstrated that patients with CIIS ≥20 and P pulmonale had increased risk of all-cause death (OR 3.38, 95% CI 1.23-9.30, p=0.019), hospitalisation or death (OR 1.61, 95% CI 1.14-2.22, p=0.004) and rate of severe COPD exacerbations (OR 1.89, 95% CI 1.22-2.91, p=0.004) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.00-1.56, p=0.046). The risk of all-cause death and cardiovascular adverse events of special interest was reduced with fluticasone furoate/umeclidinium/vilanterol versus umeclidinium/vilanterol in patients with CIIS ≥20, but not CIIS <20. CONCLUSIONS: These findings suggest the potential clinical relevance of CIIS and P pulmonale as risk indicators for adverse cardiopulmonary events in COPD.
引用
- Wade RC, Martinez FJ, Criner GJ, et al. ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD. Eur Respir J. 2025. PMID: 39467609. doi:10.1183/13993003.00171-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。